Last reviewed · How we verify
NCT01689714
A MULTI-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FOLATESCAN (TECHNETIUM Tc 99m EC20) IN PATIENTS WITH SUSPECTED OVARIAN CARCINOMA OR RECURRENT ENDOMETRIAL CARCINOMA
Phase 2 trial testing Tc 99m EC20 in Ovarian Carcinoma in 16 participants. Completed in 1 August 2005.
Quick facts
| Lead sponsor | Endocyte |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 16 |
| Start date | 1 August 2003 |
| Estimated completion | 1 August 2005 |
Drugs / interventions tested
- Tc 99m EC20 — full drug profile →
Conditions studied
- Ovarian Carcinoma — all drugs for Ovarian Carcinoma →
- Recurrent Endometrial Carcinoma — all drugs for Recurrent Endometrial Carcinoma →
Sponsor
Endocyte — full company profile →
Who can join
18 and older, female only, with Ovarian Carcinoma or Recurrent Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The folate receptor is overexpressed in many types of cancer, including ovarian and endometrial cancer, and the level of folate receptor expression increases with the stage of the disease. Technetium Tc 99m EC20 (99mTc-EC20; FolateScan), a folate-targeted diagnostic radiopharmaceutical, is designed to bind to the folate receptor. Thus, FolateScan may provide an effective method to determine folate receptor-positive (FR+) target tumors, thereby assisting in the identification of those patients who may benefit from folate-targeted therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery.
Jurczyk M, Jelonek K, Musiał-Kulik M, Beberok A, et al · · 2021 · cited 71× · PMID 33802531 · DOI 10.3390/pharmaceutics13030326 -
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.
Sharma S, Pandey MK. · · 2023 · cited 13× · PMID 37895931 · DOI 10.3390/ph16101460
Verify or expand the search:
- PubMed search for NCT01689714
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Carcinoma
Currently open trials in the same condition.
- NCT07282158 — Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians · NA · recruiting
- NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06964009 — DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer · Phase 1 · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
Other Endocyte trials
Trials by the same sponsor.
- NCT04597411 — Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer · Phase 1 · recruiting
- NCT03511664 — Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer · Phase 3 · completed
- NCT03042312 — Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy · Phase 2 · terminated
- NCT03011320 — An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery · Phase 1 · completed
- NCT01170650 — Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) · Phase 3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01689714 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Endocyte
- Last refreshed: 20 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01689714.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing